TickerFacts.

Solventum Corp (SOLV): R&D Expense

Annual figures by period end, from SEC filings.

$739.00M
Year ended 2025-12-31
$725.00M
Trailing 12 months to 2026-06-30
-1.2%
3-year compound annual growth
$775.00M2022-12-31: $767.00M2023-12-31: $758.00M2024-12-31: $775.00M2025-12-31: $739.00M$739.00M
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$739.00M-4.6%2026-02-27, From 2025-01-01
2024-12-31$775.00M+2.2%2026-02-27, From 2024-01-01
2023-12-31$758.00M-1.2%2026-02-27, From 2023-01-01
2022-12-31$767.00Mn/a2025-02-28, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Solventum Corp (SOLV)2025-12-31$739.00M-4.6%
Baxter International Inc (BAX)2025-12-31$518.00M-12.2%
ResMed Inc (RMD)2026-06-30$378.29M+14.2%
Dexcom Inc (DXCM)2025-12-31$599.10M+8.5%
Boston Scientific Corp (BSX)2025-12-31$2.05B+27.1%
Becton Dickinson & Co (BDX)2025-09-30$1.26B+6.3%
MiniMed Group, Inc. (MMED)2026-04-24$448.00M+2.8%
West Pharmaceutical Services Inc (WST)2025-12-31$74.30M+7.5%
Globus Medical Inc (GMED)2025-12-31$147.25M-10.1%

Compare SOLV, BAX, RMD, DXCM side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗